Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Audrey Griesbach

Developmental - Behavioral Pediatrics Los Angeles, CA Medical Doctor

NPI 1659597193 CMS profile 1008589

11835 W Olympic Blvd, Suite 1200E, Los Angeles, CA 90064

Open in the dashboard

General payments

$895

45 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Audrey Griesbach of Los Angeles, CA is reported in the CMS Open Payments database as having received $895 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Developmental - Behavioral Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $152 4
2024 General $86 2
2021 General $73 4
2020 General $172 12
2019 General $412 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Audrey Griesbach
  • Developmental - Behavioral Pediatrics median
  • Middle half of Developmental - Behavioral Pediatrics
  • National median

In program year 2025, general payments to Audrey Griesbach were reported at $152. Among 160 Developmental - Behavioral Pediatrics profiles paid that year, the median was $77 and the middle half received between $27 and $211.

Show as a table
Year Audrey Griesbach Developmental - Behavioral Pediatrics median Middle half National median
2019 $412 $106 $28–$315 $163
2020 $172 $55 $19–$181 $114
2021 $73 $96 $25–$343 $132
2022 $0 $86 $23–$235 $149
2023 $0 $71 $25–$348 $160
2024 $86 $74 $25–$237 $164
2025 $152 $77 $27–$211 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $250 7 payments
  2. Tris Pharma Inc $185 11 payments
  3. Neos Therapeutics, LP $184 9 payments
  4. Adlon Therapeutics L.P. $119 6 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $59 4 payments
  6. Ironshore Pharmaceuticals Inc. $58 3 payments
  7. Shire North American Group Inc $38 2 payments
  8. Retrophin, Inc. $2 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $892 42 payments
  2. Education $2 3 payments
Products named General payments · program years 2019–2025
  1. Qelbree $238 6 payments
  2. COTEMPLA XR-ODT $184 9 payments
  3. Adzenys XR-ODT $184 9 payments
  4. ADHANSIA XR $119 6 payments
  5. Dyanavel XR $77 5 payments
  6. Quillivant XR $74 4 payments
  7. VYVANSE Neuroscience $59 3 payments
  8. Vyvanse Central Nervous System (CNS) $38 3 payments
  9. Quillichew ER $34 2 payments
  10. Jornay PM 20mg capsules (Bottle of 100) $34 2 payments
  11. Other $39 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

166

Median for Pediatric Medicine: 38

Drug cost

$12,163

Median for Pediatric Medicine: $2,769

Branded share of claims

36.7%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Focalin Xr Dexmethylphenidate Hcl Brand 13 $5,025
Mydayis Dextroamphetamine/Amphetamine Brand 12 $4,639
Sertraline Hcl Generic 32 $674
Methylphenidate Hcl Er (Cd) Methylphenidate Hcl Brand 12 $467
Aripiprazole Generic 38 $455
Progesterone Progesterone, Micronized Brand 12 $374
Memantine Hcl Generic 13 $355
Spironolactone Generic 11 $91
Lorazepam Generic 11 $56
Citalopram Hbr Citalopram Hydrobromide Brand 12 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $86
$86 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record